Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient

Daniel G. Bausch, Heinz Feldmann, Thomas W. Geisbert, Mike Bray, A. G. Sprecher, Paul Boumandouki, Pierre E. Rollin, Cathy Roth

Research output: Contribution to journalArticlepeer-review

55 Scopus citations


In the 40 years since the recognition of filoviruses as agents of lethal human disease, there have been no specific advances in antiviral therapies or vaccines and few clinical studies on the efficacy of supportive care. On 20 September 2006, experts from 14 countries representing 68 institutions integrally involved in the response to outbreaks of filovirus hemorrhagic fever gathered at the National Microbiology Laboratory of the Public Health Agency of Canada in Winnipeg to discuss possible remedies for this grim situation, in a unique workshop entitled "Marburg and Ebola Hemorrhagic Fever: Feasibility of Prophylaxis and Therapy." A summary of the opportunities for and challenges to improving treatment of filovirus hemorrhagic fevers is presented here.

Original languageEnglish (US)
Pages (from-to)S136-S141
JournalJournal of Infectious Diseases
Issue numberSUPPL. 2
StatePublished - Nov 15 2007
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Outbreaks of filovirus hemorrhagic fever: Time to refocus on the patient'. Together they form a unique fingerprint.

Cite this